The latest announcement is out from Oxford BioMedica ( (GB:OXB) ).
Oxford BioMedica reported strong financial results for 2024, with a 44% increase in revenue to £128.8 million and an 81% organic growth rate. The company’s strategic expansion, including the acquisition of ABL Europe, has bolstered its global operations, particularly in viral vector platforms. The company achieved an operating EBITDA profit in the second half of 2024 and anticipates profitability for FY 2025. The growth reflects increased demand across all vector segments, with a notable rise in contracted client orders, signaling robust commercial momentum and positioning OXB for continued success in the cell and gene therapy market.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, OXB is a pioneer in viral vectors, a crucial component in the development of cell and gene therapies. The company collaborates with leading organizations worldwide to deliver life-changing therapies to patients.
YTD Price Performance: -40.34%
Average Trading Volume: 7,203
Technical Sentiment Signal: Strong Buy
Current Market Cap: $331.3M
For a thorough assessment of OXB stock, go to TipRanks’ Stock Analysis page.